全國服務(wù)咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡要描述：Vildagliptin 274901-16-5Vildagliptin, previously identified as LAF237, is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.
產(chǎn)品型號：abs47027730廠商性質(zhì)：生產(chǎn)廠家更新時間：2025-12-26訪 問 量：610產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 274901-16-5 |
|---|---|---|---|
| 分子式 | C17H25N3O2 | 純度 | ＞98% |
| 分子量 | 303.4 | 貨號 | abs47027730 |
| 規(guī)格 | 5mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is a new oral anti-hyperglycemic agent | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Vildagliptin 274901-16-5
| 產(chǎn)品描述 | |
| 描述 | Vildagliptin, previously identified as LAF237, is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucaon release by the alpha cells of the islets of Langerhans in the pancreas. It is currently in clinical trials in the U.S. and has been shown to reduce hyperglycemia in type 2 diabetes mellitus. While the drug is still not approved for use in the US, it was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions. |
| 純度 | ＞98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 維達(dá)列?。籐AF237; NVP-LAF 237 |
| 外觀 | 白色或類白色結(jié)晶性粉末 |
| 可溶性/溶解性 | DMSO : 56 mg/mL (184.6 mM) Ethanol : 56 mg/mL (184.6 mM) Water : 55 mg/mL (181.3 mM) |
| 生物活性 | |
| 靶點(diǎn) | DPP-4 |
| In vitro(體外研究) | Vildagliptin is the most stable DPP-IV inhibitor, binding in the S1- and S2-catalytic sites of DPP-IV, possessing a P-1 site transition-state mimetic. |
| In vivo(體內(nèi)研究) | Vildagliptin(orally dosed with 10 μmol/kg) is a potent, orally active inhibitor of plasma DPP-IV activity that provides increased levels of GLP-1 in an oral glucose tolerance test (OGTT) with Obese male Zucker rats. Vildagliptin orally dosed with 10 μmol/kg both significantly decreases glucose excursions and stimulates insulin secretion in Obese male Zucker rats. Maximum inhibition of plasma DPP-IV activity (95%) is observed approximately 2 hours postdose of Vildagliptin (1 μmol/kg, po) while >50% inhibition of DPP-IV is observed within 30 min postdose and persisted for >10 hours in normal Cynomolgus monkeys. Vildagliptin(60 mg/kg) increases pancreatic beta cell mass through enhanced beta cell replication and reduced apoptosis, and the increased beta cell mass is sustained for 12 days after vildagliptin washout. Vildagliptin administrated at doses of 10 mg/kg for 32 weeks protects nerve fiber loss in streptozotocin (STZ)-induced diabetic adult male Sprague Dawley rats. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | CancerCancer MetabolismResponse to hypoxia Proteolysis / UbiquitinProteolytic enzymesSerine proteaseDPPs ImmunologyAdaptive ImmunityB CellsCD ImmunologyAdaptive ImmunityT CellsCD ImmunologyCell Type MarkersCDAdhesion ImmunologyCell Type MarkersCDNon-lineage ImmunologyImmune System DiseasesAntiviral SignalingHIV-related MetabolismPathways and ProcessesMetabolism processesHypoxia MicrobiologyOrganismVirusDNA VirusssRNA positive strand virusSARS Coronavirus Stem CellsHematopoietic ProgenitorsLymphoidB Lymphocytic Lineage Stem CellsHematopoietic ProgenitorsLymphoidT Lymphocytic Lineage Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：
傳真：